WH23

WH23 (Compound WH23) potently inhibits wild-type DHRS11 with an IC₅₀ of 0.037 ± 0.0079 μM, and its binding relies heavily on hydrogen bonding with His210 of DHRS11, as evidenced by a 24-fold loss of potency against the His210Ala mutant (IC₅₀ = 0.87 μM)^[1].
WH23 inhibit CBR1 with an IC₅₀ of 1.7 nM and exhibits 46-fold selectivity for DHRS1^[1] .
WH23 (10 μM; 2-72 h) suppresses androgen signaling and proliferation in MDA-MB-453 cells by reducing AR mRNA and protein levels, inhibiting 11KAdione (HY-135794)-induced c-Myc expression, and blocking androgen-driven cell growth^[1].
WH23 (10 μM; 0.5-3 h) inhibits PI3K/AKT and MAPK signaling in MDA-MB-453 cells by reducing phosphorylation of key pathway proteins including PDK1, AKT, mTOR, and ERK^[1].
WH23 (5-20 μM; 48 h) selectively reduces viability of AR-positive MDA-MB-453 triple-negative breast cancer cells, with minimal effect on AR-negative MDA-MB-231 cells^[1].
WH23 (2-10 μM; 48 h) synergistically enhances Capivasertib (HY-15431)-induced cytotoxicity and apoptosis in Capivasertib-resistant MDA-MB-453 cells, with combination index values less than 1 confirming synergism^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.